SCHEMBL367522

SCHEMBL367522

O=C1N=CC2=CN=NC2=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3843220 0.67
SCHEMBL7057825 0.64
SCHEMBL11195 0.61
SCHEMBL6235779 0.60
SCHEMBL8466669 0.60
SCHEMBL8355288 0.60
SCHEMBL4751004 0.56
SCHEMBL1693134 0.56
SCHEMBL8623934 0.56
SCHEMBL4240975 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040203050-A1 Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression REICH NORBERT (US) 2004-10-14 US claimed
WO-2025043067-A3 PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE CARDURION PHARMACEUTICALS, INC. (US) 2025-05-08 WO disclosed
US-12251372-B2 Antileishmanial compounds, compositions and use thereof TRUSTEES OF BOSTON UNIVERSITY 2025-03-18 US disclosed
WO-2025043067-A2 PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE CARDURION PHARMACEUTICALS, INC. (US) 2025-02-27 WO disclosed
US-20240279234-A1 KINASE INHIBITORS AND RELATED METHODS OF USE UTI LIMITED PARTNERSHIP (CA) 2024-08-22 US disclosed
US-11999737-B2 Kinase inhibitors and related methods of use DUKE UNIVERSITY (US) 2024-06-04 US disclosed
WO-2024107445-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES, INC. (US) 2024-05-23 WO disclosed
WO-2023230217-A1 ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-11-30 WO disclosed
US-20230381142-A1 ANTILEISHMANIAL COMPOUNDS, COMPOSITIONS AND USE THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2023-11-30 US disclosed
US-20230192708-A1 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES IDORSIA PHARMACEUTICALS LTD (CH) 2023-06-22 US disclosed
EP-0995751-A2 Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction PFIZER INC. (US) 2000-04-26 EP disclosed
US-6028074-A FOR TREATING ALLOGRAFT REJECTION ASTRA PHARMACEUTICALS, LTD. (GB) 2000-02-22 US disclosed
EP-0496617-B1 Adenosine kinase inhibitors METABASIS THERAPEUTICS INC (US) 1999-12-01 EP disclosed
EP-0682519-A4 ADENOSINE KINASE INHIBITORS. GENSIA INC (US) 1997-12-17 EP disclosed
US-5646128-A TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS GENSIA, INC. (US) 1997-07-08 US disclosed
EP-0682519-A1 ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1995-11-22 EP disclosed
WO-1994017803-A9 ADENOSINE KINASE INHIBITORS 1994-09-29 WO disclosed
WO-1994017803-A1 ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1994-08-18 WO disclosed
WO-1992012718-A1 ADENOSINE KINASE INHIBITORS GENSIA, INC. (US) 1992-08-06 WO disclosed
EP-0496617-A1 Adenosine kinase inhibitors GENSIA, INC. (US) 1992-07-29 EP disclosed